Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by micro PET

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4758-4766

  Li, Zi Bo ^a   Niu, Gang ^a   Wang, Hui ^a   He, Lina ^a   Yang, Lily ^b   Ploug, Michael ^c   Chen, Xiaoyuan ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FINSEN LABORATORY   (Denmark)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AE 105; COPPER 64; GLUTAMIC ACID; PROTEIN INHIBITOR; TRYPTOPHAN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CELL SURFACE RECEPTOR; COPPER; PEPTIDE; SINGLE HETEROCYCLIC RINGS; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SURFACE PLASMON RESONANCE; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CHEMISTRY; INSTRUMENTATION; KINETICS; METHODOLOGY; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE;

EID: 51049094210     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4434     Document Type: Article

References (43)

1. Rølash;mer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-76.
2. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003;9: 1499-528.
3. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60: 636-43.
4. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 1993;53:135-44.
5. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996;77:1079-88.
6. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 2000;157:1219-27.
7. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000;61:1-12.
8. Solberg H, Ploug M, Høyer-Hansen G, Nielsen BS, Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001;49:237-46.
9. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
10. Law B, Curino A, Bugge TH. Weissleder R. Tung CH. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem Biol 2004;11:99-106.
11. Law B, Hsiao JK, Bugge TH. Weissleder R. Tung CH. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Anal Biochem 2005;338:151-8.
12. Hsiao JK, Law B, Weissleder R, Tung CH. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. J Biomed Opt 2006;11: 34013.
13. Ploug M, Østergaard S, Gårdsvoll H, et al. Peptidederived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001;40:12157-68.
14. McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem 2005;12:807-18.
15. Gårdsvoll H, Werner F, Søndergaard L, Danø K, Ploug M. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expr Purif 2004;34:284-95.
16. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266:1926-33.
17. Jacobsen B, Gårdsvoll H, Juhl Funch G, Østergaard S, Barkholt V, Ploug M. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Protein Expr Purif 2007;52:286-96.
18. Gårdsvoll H, Gilquin B, Le Du MH, Menez A, Jørgensen TJ, Ploug M. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem 2006;281:19260-72.
19. Wu Y, Zhang X, Xiong Z, et al. micro PET imaging of glioma integrin avb3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46:1707-18.
20. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004;47:1465-74.
21. Ma D, Lu F, Overstreet T, Milenic DE, Brechbiel MW. Novel chelating agents for potential clinical applications of copper. Nucl Med Biol 2002;29:91-105.
22. Mirick GR, O'Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol 1999;26:841-5.
23. Llinas P, Le Du MH, Gårdsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005;24:1655-63.
24. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266:12752-8.
25. Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Commun 1990;2:173-9.
26. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999:91:869-74.
27. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62:2390-7
28. Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-l receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65:7775-81.
29. Min HY Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56: 2428-33.
30. Tressler RJ, Pitot PA, Stratton JR, et al. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999;107: 168-73.
31. Kobayashi H, Sugino D, She MY, et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain Il of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998;253:817-26.
32. Kruger A, Soeltl R, Lutz V, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9.
33. Go Y, Chintala SK, Mohanam S, et al. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 1997;15:440-6.
34. Mohanam S. Chintala SK, Go Y et al. in vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997;14:1351-9
35. Engelhard H, Narang C, Homer R, Duncan H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 1996;227:400-5.
36. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 2004;1:165-76.
37. Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol 2005;15:327-41.
38. Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells Int J Oncol 2006;28:831-9
39. Piironen T, Laursen B, Pass J, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004;50 2059-68.
40. Ploug M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 1998; 37:16494-505.
41. Ploug M, Østergaard S, Hansen LB, Holm A, Dano K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligandbinding site and a short interdomain separation Bio chemistry 1998;37:3612-22.
42. Høyer-Hansen G. Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007; 44:65-102.
43. Quax PH, Grimbergen JM. Lansink M, et al. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler Thromb Vasc Biol 1998; 18:693-701.